ARDX (Ardelyx, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ARDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-06-22 | Laura A Williams | Chief Patient Officer | MIXED | — | — |
| 2026-06-18 | DAVID M MOTT | Director | A | — | — |
| 2026-06-18 | William C JR Bertrand | Director | A | — | — |
| 2026-06-18 | Muna Bhanji | Director | A | — | — |
| 2026-06-18 | Onaiza Cadoret-Manier | Director | A | — | — |
| 2026-06-18 | Richard J Rodgers | Director | A | — | — |
| 2026-06-18 | Merdad Parsey | Director | A | — | — |
| 2026-06-18 | Robert B Bazemore | Director | A | — | — |
| 2026-06-17 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-05-22 | James Parker Brady | Chief Human Resources Officer | Sell | — | — |
| 2026-05-22 | Eric Duane Foster | Chief Commercial Officer | Sell | — | — |
| 2026-05-22 | Joseph James Reilly | See Remarks | Sell | — | — |
| 2026-05-22 | Mike Kelliher | Chief Business Officer | Sell | — | — |
| 2026-05-22 | Susan Hohenleitner | Chief Financial Officer | Sell | — | — |
| 2026-05-22 | MICHAEL RAAB | President & CEO | Sell | — | — |
| 2026-05-22 | John E Bishop | See Remarks | Sell | — | — |
| 2026-05-22 | Laura A Williams | Chief Patient Officer | Sell | — | — |
| 2026-05-19 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-04-17 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-03-18 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-02-25 | MICHAEL RAAB | President & CEO | MIXED | — | — |
| 2026-02-23 | John E Bishop | See Remarks | Sell | — | — |
| 2026-02-23 | Joseph James Reilly | See Remarks | Sell | — | — |
| 2026-02-23 | Laura A Williams | See Remarks | Sell | — | — |
| 2026-02-23 | MICHAEL RAAB | President & CEO | Sell | — | — |
| 2026-02-23 | Mike Kelliher | See Remarks | Sell | — | — |
| 2026-02-23 | James Parker Brady | Chief Human Resources Officer | Sell | — | — |
| 2026-02-23 | Eric Duane Foster | Chief Commercial Officer | Sell | — | — |
| 2026-02-23 | DAVID M MOTT | Director | Buy | — | — |
| 2026-02-23 | Susan Hohenleitner | Chief Financial Officer | Sell | — | — |
| 2026-01-27 | Joseph James Reilly | See Remarks | A | — | — |
| 2026-01-26 | John E Bishop | See Remarks | A | — | — |
| 2026-01-26 | James Parker Brady | Chief Human Resources Officer | A | — | — |
| 2026-01-26 | Laura A Williams | Chief Patient Officer | A | — | — |
| 2026-01-26 | Eric Duane Foster | Chief Commercial Officer | A | — | — |
| 2026-01-26 | MICHAEL RAAB | President & CEO | A | — | — |
| 2026-01-26 | Mike Kelliher | See Remarks | A | — | — |
| 2026-01-26 | Susan Hohenleitner | Chief Financial Officer | A | — | — |
| 2026-01-09 | Laura A Williams | Chief Patient Officer | MIXED | — | — |
| 2025-11-25 | Laura A Williams | Chief Patient Officer | Sell | — | — |
| 2025-11-25 | MICHAEL RAAB | President & CEO | Sell | — | — |
| 2025-11-25 | ELIZABETH A GRAMMER | See Remarks | Sell | — | — |
| 2025-11-25 | Mike Kelliher | See Remarks | Sell | — | — |
| 2025-11-25 | Joseph James Reilly | See Remarks | Sell | — | — |
| 2025-11-25 | Eric Duane Foster | Chief Commercial Officer | Sell | — | — |
| 2025-08-28 | Mike Kelliher | Chief Business Officer | Sell | — | — |
| 2025-08-28 | Laura A Williams | Chief Patient Officer | MIXED | — | — |
| 2025-08-25 | Laura A Williams | Chief Patient Officer | Sell | — | — |
| 2025-08-25 | Eric Duane Foster | Chief Commercial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,579,210 | — |
| — | 10%+ Owner | 9,169,210 | — |
| — | 10%+ Owner | 8,752,543 | — |
| — | 10%+ Owner | 8,541,623 | — |
| — | 10%+ Owner | 8,097,725 | — |
| — | 10%+ Owner | 8,086,401 | — |
| — | 10%+ Owner | 7,489,426 | — |
| — | Director | 6,831,841 | — |
| — | 10%+ Owner | 6,207,480 | — |
| — | 10%+ Owner | 3,482,186 | — |
| — | 10%+ Owner | 3,482,186 | — |
| — | 10%+ Owner | 3,082,186 | — |
| — | 10%+ Owner | 3,082,186 | — |
| — | 10%+ Owner | 3,082,186 | — |
| — | 10%+ Owner | 3,082,186 | — |
| — | 10%+ Owner | 3,082,186 | — |
| — | 10%+ Owner | 2,839,706 | — |
| — | 10%+ Owner | 2,539,706 | — |
| — | President & CEO | 1,721,034 | — |
| — | Director | 910,339 | — |
| — | Chief Patient Officer | 460,093 | — |
| — | Chief Commercial Officer | 449,092 | — |
| — | Chief Development Officer | 448,378 | — |
| — | Director | 439,998 | — |
| — | Chief Commercial Officer | 417,972 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARDX quote page; the site-wide leaderboard is on the insider transactions hub.